Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

High-dose steroids do not always cause bone loss in children

26.08.2004


Study of kidney condition challenges conventional view of steroid effects

Children who take steroid drugs for a kidney condition called nephrotic syndrome do not suffer bone loss, a common side effect of steroid treatments in adults. A new study sheds light on the steroid’s mixed effects: the drug frequently causes obesity, which seems to protect children against bone loss.

Childhood nephrotic syndrome, which affects 3 out of 100,000 children, is the most common chronic kidney disease in children. Although it does not impair kidney function, it weakens the body’s ability to remove water and salt from the blood, and causes swelling in the belly, legs, and around the eyes.



Left untreated, the syndrome may progress to life-threatening complications. Fortunately, most cases of childhood nephrotic syndrome are steroid-sensitive, meaning that a corticosteroid drug such as prednisone relieves the symptoms. Furthermore, nephrotic syndrome usually disappears by the later teen years, with no permanent kidney damage.

"Unlike other childhood diseases treated with steroid drugs, such as inflammatory bowel disease or juvenile rheumatoid arthritis, nephrotic syndrome resolves quickly when treated," said pediatric nephrologist Mary B. Leonard, M.D., of The Children’s Hospital of Philadelphia, lead author of the study. "We specifically chose steroid-sensitive nephrotic syndrome because we are able to isolate the drug’s effects on bones, without having an underlying systemic disease simultaneously affecting the bones."

The team led by Dr. Leonard compared 60 children and adolescents with steroid-sensitive nephrotic syndrome to 195 healthy children. Specialized X-ray measurements showed no signs of osteoporosis, a loss in bone mass, among the nephrotic syndrome patients. The study appeared in the August 26 New England Journal of Medicine.

The researchers made adjustments for body mass index, an important consideration, since 38 percent of the children in the nephrotic syndrome sample were obese (in contrast, only 16 percent of the control subjects were obese, a proportion consistent with the general pediatric population). The disproportionate obesity among children with nephrotic syndrome disappears after the patients discontinue steroid treatments.

"While steroids tend to make children shorter and heavier than healthy children, increased weight is associated with an increase in bone mass," said co-author Babette Zemel, Ph.D., of the Nutrition Center at Children’s Hospital. Specifically, whole-body measurements of bone mineral content were higher in children with nephrotic syndrome than in healthy children.

A possible explanation for the increased bone mass, she added, is that the extra physical load imposed by higher weight may stimulate the bones to grow stronger. Obesity may also induce hormones to increase bone mass.

Bone health in childhood strongly influences bone health in later life--including the degree to which older adults are vulnerable to osteoporosis-related fractures. "This report may help reassure doctors and parents that using steroids to treat children with nephrotic syndrome does not raise their risk of osteoporosis," said Dr. Leonard. "There is some evidence that obesity raises a child’s risk of fracture, but this may be due to the force of a heavy child falling on an outstretched arm--and not to a weakening of the bone."

In other childhood diseases treated with steroids, such as inflammatory bowel disease and juvenile rheumatoid arthritis, researchers have found bone loss in children. The authors suggest those underlying diseases, which involve systemic, persistent inflammation, may damage bones in a way that nephrotic syndrome does not. Drs. Leonard and Zemel are continuing their pediatric bone studies with more refined computed tomography (CT) techniques that provide richer data than the two-dimensional images produced by X-ray studies.

Co-authors with Drs. Leonard and Zemel, also from Children’s Hospital, were Justine Shults, Ph.D.; Bethany J. Foster, M.D.; and Virginia A. Stallings, M.D. Harold I. Feldman, M.D., and all the co-authors were also from the University of Pennsylvania School of Medicine. Grants from the National Institute of Health supported the study.

Joey Marie McCool | EurekAlert!
Further information:
http://www.chop.edu

More articles from Health and Medicine:

nachricht Remdesivir prevents MERS coronavirus disease in monkeys
14.02.2020 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Recent advances in addressing tuberculosis give hope for future
12.02.2020 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

Im Focus: Quantum fluctuations sustain the record superconductor

Superconductivity approaching room temperature may be possible in hydrogen-rich compounds at much lower pressures than previously expected

Reaching room-temperature superconductivity is one of the biggest dreams in physics. Its discovery would bring a technological revolution by providing...

Im Focus: New coronavirus module in SORMAS

HZI-developed app for disease control is expanded to stop the spread of the pathogen

At the end of December 2019, the first cases of pneumonia caused by a novel coronavirus were reported from the Chinese city of Wuhan. Since then, infections...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Electric solid propellant -- can it take the heat?

14.02.2020 | Physics and Astronomy

Pitt study uncovers new electronic state of matter

14.02.2020 | Physics and Astronomy

Researchers observe quantum interferences in real-time using a new extreme ultra-violet light spectroscopy technique

14.02.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>